The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to update their vaccines.

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.The vaccine's prospects were thrown into doubt after the FDA missed its April 1 target to approve the shot,